NCT05098275

Phamacokinetics and Safety Profiles of DA-5210 10/500mg in Healthy Subjects at Fed State

An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of DA-5210 10/500mg in Healthy Subjects at Fed State

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Phamacokinetics and safety profiles of DA-5210 10/500mg in Healthy subjects at Fed State

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	DA-5210 10/500mg	single dose administration (one tablet once a day)
DRUG	DA-5210-R 10/500mg	single dose administration (one tablet once a day)

Timeline

• Start date: 2021-10-26
• Primary completion: 2022-02-06
• Completion: 2022-02-06
• First posted: 2021-10-28
• Last updated: 2022-06-06

Locations

1 site across 1 country: South Korea